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Abstract
Background
Adverse drug reactions (ADRs) are important causes of morbidity and mortality in the
healthcare system; however, there are no studies reporting on the magnitude and risk fac-
tors associated with ADR-related hospitalisation in Ethiopia.
Objectives
To characterise the reaction types and the drugs implicated in admission to Jimma Univer-
sity Specialized Hospital, Southwest Ethiopia, and to identify risk factors associated with
ADR-related hospitalisation.
Methods
A prospective cross-sectional study was conducted from May 2015 to August 2016 among
consenting patients aged18 years consecutively admitted to medical wards taking at least
one medication prior to admission. ADR-related hospitalisations were determined through
expert review of medical records, laboratory tests, patient interviews and physical observa-
tion. ADR causality was assessed by the Naranjo algorithm followed by consensus review
with internal medicine specialist. ADR preventability was assessed using Schumock and
Thornton’s criteria. Only definite and probable ADRs that provoked hospitalisation were
considered. Binary logistic regression was used to identify independent predictors of ADR-
related hospitalisation.
Results
Of 1,001 patients, 103 (10.3%) had ADR-related admissions. Common ADRs responsible
for hospitalisation were hepatotoxicity (35, 29.4%) and acute kidney injury (27, 22.7%). The
drug classes most frequently implicated were antitubercular agents (45, 25.0%) followed by
antivirals (22, 12.2%) and diuretics (19, 10.6%). Independent predictors of ADR-related hos-
pitalisation were body mass index (BMI) <18.5 kg/m2 (adjusted odd ratio [AOR] = 1.69; 95%
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confidence interval [CI] = 1.10–2.62; p = 0.047), pre-existing renal disease (AOR = 2.84;
95%CI = 1.38–5.85, p = 0.004), pre-existing liver disease (AOR = 2.61; 95%CI = 1.38–4.96;
p = 0.003), number of comorbidities4 (AOR = 2.09; 95%CI = 1.27–3.44; p = 0.004),
number of drugs6 (AOR = 2.02; 95%CI = 1.26–3.25; p = 0.004) and history of previous
ADRs (AOR = 24.27; 95%CI = 11.29–52.17; p<0.001). Most ADRs (106, 89.1%) were
preventable.
Conclusions
ADRs were a common cause of hospitalisation. The majority of ADRs were preventable,
highlighting the need for monitoring and review of patients with lower BMI, ADR history,
renal and liver diseases, multiple comorbidities and medications. ADR predictors should be
integrated into clinical pathways and pharmacovigilance systems.
Introduction
Adverse drug reactions (ADRs) are one of the leading causes of morbidity and mortality in the
healthcare system [1]. Globally, studies have reported that the overall prevalence of ADR-
related hospitalisation varies from 0.2% [2] to 54.5% [3]. A recent review of 43 observational
studies identified a comparable prevalence of ADR-related hospitalisation in developed and
developing countries [1]. However, most of the studies included in this review were conducted
in developed countries, where the disease characteristics and prevalence, access to medicines,
drug use patterns and management systems differ markedly from those in developing coun-
tries [4]. With respect to potential risk factors for ADRs, developing countries differ from
developed countries in several important areas. These include greater proportions of patients
taking antituberculosis (anti-TB) and antiretroviral therapy (ART) [5], a high prevalence of
anaemia and malnutrition [6], widespread use of traditional remedies [7], a higher incidence
of concomitant anti-TB drugs and ART with overlapping adverse effects [6], and increasing
rates of concomitant infectious and non-communicable diseases demanding multiple medica-
tions with potential interactions [8–12]. There are also higher frequencies of genetic variants
conferring increased risk for ADRs for commonly used drugs treating cancer, human immu-
nodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS) and tuberculosis
(TB) in persons of African descent [13].
In Ethiopia, a developing country, the risk of ADR-related hospitalisation is a health con-
cern due to an increasing number of patients eligible for anti-TB and ART, due to decentralisa-
tion and scale-up of the HIV/AIDS care programme [14], and concomitant drug management
of HIV/TB co-infected patients [14]. According to a 2014 World Health Organization (WHO)
report, the prevalence of all forms of TB was 211 per 100,000 of the population, of whom 13%
of patients were HIV co-infected [15]. The prevalence of HIV among the adult population in
2015 was estimated to be 1.0% with national ART coverage of 52.0% [16]. There is growing
attention to chronic diseases management with multiple medications [11, 17]. The use of new
and complex therapies for chronic diseases has increased due to the establishment of commu-
nity care programmes [18] and strengthening of health systems for chronic care at the level of
local health centres, primary, general, and specialised hospitals [18]. The provision of primary
health care services by health extension workers (health professionals working at the lowest
health care level targeting preventive and curative health services at the household level) [19]
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and the expansion of community pharmacies and drug stores at the community level has
remarkably increased medication access and use in the community, although medication regu-
lation is poor [20]. There are also higher rates of drug-related problems [21] and irrational use
of medicines [22] among patients with chronic illnesses in ambulatory care clinics that could
lead to drug-related harm.
Studies have identified several factors contributing to ADR-related hospitalisations includ-
ing older age [23, 24], female gender [25, 26], increased number of co-morbidities [27, 28],
increased number of medications [29, 30], renal diseases [31, 32], liver diseases [33], heart fail-
ure [28], higher Charlson Comorbidity Index (CCI) [34], presence of chronic illnesses [35,
36], and history of previous ADRs [37, 38]. HIV/AIDS patients taking ART have been identi-
fied as a risk factor for ADR-related hospitalisations only in developing countries [8, 39].
Drugs commonly reported as contributing to ADRs include anticoagulants [24, 40], non-ste-
roidal anti-inflammatory drugs (NSAIDs) [41], and angiotensin-converting enzyme inhibitors
[41]. However, studies focussing on risk factors for ADR-related hospitalisation in developing
countries are very limited in number [1]. Therefore, identification and reporting of factors
contributing to ADR-related hospitalisation for community-based patients is crucial to
develop preventive strategies to decrease the burden in the developing world [9, 10].
To our knowledge, there are no studies reporting on the prevalence and risk factors associ-
ated with ADR-related hospitalisation in Ethiopian patients. Thus, the main aim of this study
was to characterise the reaction types and the drugs implicated in admission to Jimma Univer-
sity Specialized Hospital (JUSH), Southwest Ethiopia, and to identify risk factors associated
with ADR-related hospitalisation.
Methods
Study setting, design and population
This study was conducted at the JUSH, which is the major public hospital in southwest Ethio-
pia with a catchment population of about 15 million people [42].
A prospective cross-sectional study was conducted from May 2015 to August 2016. Con-
senting patients with complete medical records aged18 years and taking at least one medica-
tion prior to admission to medical wards were included in the study. Patients were excluded if
they were unwilling to participate, unable to be interviewed due to health or other reasons, not
taking at least one medication prior to admission and had incomplete medical and medication
records.
Data collection
One of the authors (MTA) interviewed consecutively admitted patients as soon as practical
for socio-demographic information, social drug use, medical history, drug allergies, use of
over-the-counter and herbal medicines (S1 Table). Patients’ medical records were reviewed
for admission diagnosis, ADR history, and clinical data within 48 hours of admission. Medi-
cation exposure in the month preceding hospitalisation was obtained through review of
patients’ medical records and /or interview with the patient or family members. Common
laboratory tests were evaluated within 48 hours of admission for each patient case including:
renal function (serum creatinine mg/dL, blood urea nitrogen mg/dL and estimated glomeru-
lar filtration rate (eGFR) mL/min/1.73m2), liver function (alanine transaminase IU/L, aspar-
tate transaminase IU/L, alkaline phosphatase IU/L and total bilirubin mg/dL) and complete
blood count (white blood cell count cells/mm3, red blood cell count cells/mm3, haemoglobin
g/dL, haematocrit %, and platelet count cells/mm3). Parameters describing nutritional and
metabolic status (serum albumin g/dL, total triglyceride mg/dL, low-density lipoprotein
ADR-related hospitalisation in Ethiopia
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mg/dL, high-density lipoprotein mg/dL, glucose mg/dL), serum electrolytes (serum calcium
mmol/L, potassium mmol/L and sodium mmol/L) and coagulation status (prothrombin
time) were recorded. Vital statistics such as body temperature, blood pressure, respiratory
rate and pulse rate were recorded at admission. Other diagnostic data, such as echocardiog-
raphy, ultrasound, electrocardiogram and viral markers and urinalysis results, were also
evaluated.
Definitions of terms and variables used
The WHO definition of an ADR was used in this study: “any response to a drug which is
noxious and unintended, and which occurs at doses normally used in man for prophylaxis,
diagnosis, or therapy of disease, or for the modification of physiological function” [43]. This
definition excludes treatment failure, drug abuse, intentional drug overdose and accidental
or self-poisoning. Alcohol consumption was recorded as number of standard drinks per day.
Khat chewing, which was of interest as it contributes to elevated blood pressure [44], was
defined as regular chewer if a patient chewed khat at least four times per week. Drugs were
classified using the WHO Anatomical Therapeutic Chemical Classification (ATC) System
[45] and diagnoses were coded according to International Classification of Primary Care 2nd
edition [46]. Calculation of the number of medications was based on the number of active
ingredients in single and combination products [47]. A cut off point for polypharmacy was
6 medications [48]. A cut off point for comorbidities was4 diseases based on a similar
study [39]. Adult nutritional status was assessed using the body mass index (BMI) [49] and
classified as <18.5 kg/m2 and 18.5 kg/m2 for analysis purpose. Patients were considered to
have pre-existing chronic kidney disease if the eGFR was <60 mL/minute/1.73m2 and they
had documented abnormal renal ultrasound (abnormal renal echogenicity or kidney size or
presence of cysts) for at least 3 months prior to admission [50]. Drug-induced acute kidney
injury was suspected among patients with baseline renal insufficiency (eGFR < 60 mL/min-
ute/1.73m2), volume depletion and multiple exposures to nephrotoxic agents prior to admis-
sion, as long as other potential causes were excluded. Chronic liver disease was considered
pre-existing if liver diseases (such as cirrhosis, chronic viral hepatitis) or liver dysfunction or
liver injury were documented by the treating physician prior to admission [33]. Drug-
induced hepatotoxicity was suspected when aspartate aminotransferase (AST) or alanine
aminotransferase (ALT) levels were 3 or more times the upper normal limit (UNL) or total
bilirubin was 2 or more times UNL [51], as long as other potential causes were excluded. The
response to rechallenge or re-exposure to some drugs, such as anti-TB drugs, were imple-
mented based on the WHO guidelines for the treatment of TB [52]. HIV/AIDS and TB
patients were those patients diagnosed with HIV/AIDS and TB, respectively, and taking
ART and anti-TB drugs prior to the current admission. All comorbidities were defined as
present if documented in the medical records. A patient who had studied at least to a primary
school level and was able to read and write in the local language(s) was considered as edu-
cated, whereas other patients were considered uneducated. According to the Ethiopian con-
text, cities and small towns were considered as urban areas while rural villages or other
similar clusters were considered as rural areas.
Identifying ADRs as a cause for hospitalisation
The primary researcher (MTA) evaluated all patients admitted to medical wards during the
study period to assess if the admission had been caused by an ADR. The identification of
whether one or more drugs led to the hospitalisation was based on a review of medical records,
evaluation of laboratory tests, interview with patients or family members about medication
ADR-related hospitalisation in Ethiopia
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usage and physical observation. An ADR was suspected if there was a relationship between the
time of drug administration and the onset and course of the adverse reaction, while excluding
other potential causes. The known adverse reaction profile of each drug was evaluated based
on Ethiopian National Drug Formulary (2014), British National Formulary [53] and Up-To-
Date 19.3 [54]. Confirmation of the causal relationship of an ADR to the suspected medication
was performed using the Naranjo ADR assessment scale [55]. Applying the Naranjo algorithm,
ADRs were classified as definite (9–12 points), probable (5–8 points), possible (1–4 points), or
doubtful (0 points). The senior supervising internal medicine specialist (DY) independently
and blindly reviewed all cases of suspected ADRs and cases without suspected ADRs for the
presence of ADRs and to confirm the Naranjo rating using a similar approach to other studies
[56, 57]. The primary researcher (MTA) and the senior supervising internal medicine specialist
met to reach a consensus decision on the presence of an ADR-related admission and excluded
possible and doubtful cases. When consensus was not reached on the causality assessment, an
additional clinical pharmacy specialist’s opinion was sought for majority decision. Only defi-
nite and probable ADRs that provoked hospitalisation were considered. ADRs were assessed
for preventability using Schumock and Thornton criteria [58] through the same approach.
ADRs were classified as type A (dose dependent, augmented pharmacological and predictable
reactions) and type B (bizarre, dose independent and non-predictable reactions) according to
the Rawlins and Thompson classification method [59]. ADRs observed during the hospital
stay were excluded.
Data analysis and interpretation
Data was recorded into an Access database (2016, Microsoft, Redmond, Washington) and ana-
lysed using the IBM Statistical Package for the Social Science (IBM SPSS version 23.0 Inc., Chi-
cago, Illinois). Frequency of adverse reaction types and drugs implicated were determined.
The chi-square test or Fisher’s exact test were used to compare categorical data between ADR-
and non-ADR patients. For non-normally distributed variables, comparisons were undertaken
with Mann-Whitney tests and the results were presented as medians and interquartile ranges
(IQR). For normally distributed continuous variables, comparisons were performed using Stu-
dent’s t-tests with results presented as means and standard deviations (SD).
Independent variables were assessed for multicollinearity and association to rule out corre-
lation between two or more independent variables using variance inflation factor. Independent
variables with p<0.25 in univariate analyses were entered into a multivariable binary logistic
regression model to determine independent predictors of ADR-related hospitalisation. The
performance of the ADR-related admission risk prediction model was assessed using the area
under the receiver operator curve (AUROC), which assesses the ability of independent risk
score to predict ADR-related admissions. The ROC curve was prepared using R (2015, R
Foundation for Statistical Computing, Vienna) [60]. A p value of<0.05 was considered statis-
tically significant in all analyses.
Ethics
The study was approved by the Tasmanian Health and Medical Human Research Ethics Com-
mittee (reference number H0014718) and the Jimma University Institutional Review Board
(reference number RPGC/58/2015). We received permission from Jimma University Special-
ised Hospital management to conduct the research. Written informed consent was obtained
from all individual participants included in the study.
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Results
General information
A total of 3,224 patients were screened; 2,223 patients were excluded due to age<18 years
(255), not taking at least one medication prior to admission (576), incomplete medical and
medication records (70), unwillingness to participate (463) and inability to be interviewed as a
result of health or other reasons (859). Of the 1,001 patients who met the inclusion criteria,
103 (10.3%) were deemed to have experienced an ADR-related admission (Fig 1).
One hundred and nineteen ADRs were identified among the 103 patients, equating to 1.2
ADRs per patient. Of these, 26.1% were definite and 73.9% were probable. Most ADRs (106,
89.1%) were considered preventable. Ninety-nine (83.2%) of the ADRs were considered
pharmacologically predictable (type-A reactions) (Table 1).
ADR characteristics and drugs implicated in ADRs
The most common ADRs responsible for hospital admissions were hepatotoxicity (35, 29.4%)
followed by acute kidney injury (severely declined glomerular filtration rate and hypovolemia)
(27, 22.7%), skin reactions (8, 6.7%), hypokalaemia (7, 5.9%) and gastrointestinal bleeding or
gastritis (7, 5.9%). Commonly implicated drugs in hepatotoxicity were isoniazid (21, 11.7%)
Fig 1. The diagram outlining patient screening and identification of ADR-related admissions.
https://doi.org/10.1371/journal.pone.0186631.g001
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followed by pyrazinamide (18, 10.0%), efavirenz (5, 2.8%) and atorvastatin (5, 2.8%). Com-
monly implicated drugs in acute kidney injury were tenofovir (9, 5.0%), furosemide (7, 3.9%),
and enalapril (7, 3.9%). The drugs most commonly suspected of causing skin reactions were
sulfamethoxazole (2, 1.1%), trimethoprim (2, 1.1%) and rifampicin (2, 1.1%). The drug most
commonly suspected of causing hypokalaemia was furosemide (6, 3.3%). The drugs most com-
monly suspected of causing gastrointestinal bleeding were warfarin (3, 1.7%), heparin (3,
1.7%) and diclofenac (3, 1.7%). In general, anti-TB agents constituted the major source of
ADRs (45, 25.0%) followed by antivirals (22, 12.2%) and diuretics (19, 10.6%). Table 2 provides
a summary of ADRs and causative agents.
Drugs used
Out of the 4,018 drugs used by the 1,001 patients, 562 (14.0%) were used by patients who expe-
rienced ADR-related admissions. One-hundred and eighty of the 562 drugs were implicated
in the 119 ADRs. Anti-infectives constituted the major proportion (52.1% versus 40.5%,
p = 0.001) followed by cardiovascular system agents (18.9% versus 24.9%, p = 0.013) in both
the ADR and non-ADR groups, respectively (Table 3).
Patient characteristics in univariate analysis
The main socio-demographic difference between the ADR-and non-ADR groups was a differ-
ence in urban versus rural residence (P = 0.004), where urban residents were more likely to be
admitted with ADRs than rural residents. The mean body mass index (kg/m2) was lower in the
ADR group, 19.1±2.8 versus 20.1±2.9, p = 0.004. There was no difference between the ADR
and non-ADR groups for age, gender, educational status, smoking, alcohol use, khat chewing
and herbal use. Patients with a previous ADR history (p<0.001), pre-existing renal diseases
(p = 0.003), pre-existing liver diseases (p<0.001), TB taking anti-TB drugs (p<0.001) and
HIV/AIDS taking ART (p<0.001) were more likely to be admitted with ADRs than those
without these risk factors. Similarly, ADR admission was more likely in patients who had been
hospitalised in the preceding 3 months (p = 0.030). Patients in the ADR group had a more
comorbidities (4.0±1.4 versus 3.2±1.2, p<0.001) and used more drugs than the non-ADR
group (5.5±2.7 versus 3.9±2.1, p<0.001) (Table 4).
Factors associated with ADR-related admissions
Variables included in the multivariable binary logistic regression model were those with
p<0.25 in the univariate analyses. There was no multicollinearity identified in the included
Table 1. Causality, type and preventability of ADRs causing hospitalisation (N = 119).
ADR classifications n (%)
Causality of ADRs
Definite 31(26.1)
Probable 88 (73.9)
Preventability scale
Not preventable 13 (10.9)
Definitely preventable 19 (16.0)
Probably preventable 87 (73.1)
Rawlins classification of reaction
Type A (pharmacologically predictable) 99 (83.2)
Type B (pharmacologically non-predictable) 20 (16.8)
https://doi.org/10.1371/journal.pone.0186631.t001
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variables. Six risk factors associated with ADR-related hospitalisation were identified in the
multivariable binary logistic regression model: BMI< 18.5kg/m2, pre-existing renal diseases,
pre-existing liver diseases, number of diagnoses4, number of medications6 and previous
ADR history (Table 5). The ADR-related admission risk prediction model was found to have
an AUROC of 79.0% (95% CI 73.9%-84.1%) (S1 Fig). The model had a sensitivity of 59.2% and
specificity of 86.6%, suggesting that it can moderately rule-in patients at risk of ADRs and
strongly rule-out those patients not at risk of ADRs.
Discussion
Identification and reporting of predictors of ADR-related hospitalisation for community-
based patients is crucial to develop preventive strategies and responsible care of patients. Medi-
cal practitioners may lack awareness of factors predicting ADRs leading to hospitalisation [61,
62]. To overcome this, studies, mainly from developed countries [28, 37], have identified sev-
eral predictors of ADRs causing hospitalisation. However, Ethiopia is a developing country
with different healthcare issues. These issues include a lesser ability to provide healthcare [19],
Table 2. ADRs (N = 119) and implicated drugs (N = 180).
ADR types n (%) Drugs implicated in causing ADRs (n) n (%)
Hepatotoxicity (cholestatic (22), hepatocellular (8), and
mixed (5))
35
(29.4)
Isoniazid (21), pyrazinamide (18), atorvastatin (5), efavirenz (5), acetyl
salicylic acid (ASA)# (2), clopidogrel (2), propylthiouracil (2), paracetamol
(2), phenytoin (2), rifampicin (1), omeprazole (1), ritonavir (1), atazanavir
(1)
63
(35.0)
Acute kidney injury (27), and lactic acidosis (1) 28
(23.5)
Tenofovir (9), furosemide (7), enalapril (7), diclofenac (4), acetyl salicylic
acid# (4), cimetidine (1), heparin (1), clopidogrel (1), metformin^ (1)
35
(19.4)
Skin reactions involving mucous membrane (pleuritic skin
eruption (2), rash (5) and Steven Johnson Syndrome(1))
8 (6.7) Sulfamethoxazole (2), rifampicin (2), trimethoprim (2), ciprofloxacin* (1),
ampicillin (1), isoniazid (1), nevirapine (1), methotrexate (1), cloxacillin (1),
phenytoin (1), phenobarbital (1), warfarin (1)
15
(8.3)
Gastrointestinal bleeding (6) and gastritis (1) 7 (5.9) Warfarin (3), heparin (3), diclofenac (3), clopidogrel (2), acetylsalicylic acid#
(2), propylthiouracil (1), glibenclamide (1)
15
(8.3)
Hypokalaemia 7 (5.9) Furosemide (6), insulin (3), digoxin (1) 10
(5.6)
Hypocalcaemia 6 (5.0) Furosemide (6) 6 (3.3)
Diarrhoea 5 (4.2) Lamivudine (3), rifampicin (2), amitriptyline (1) 6 (3.3)
Hypoglycaemia 4 (3.4) Insulin (4), glibenclamide (1), acetyl salicylic acid (1) 6 (3.3)
Anaemia 4 (3.4) Sulfamethoxazole (2), trimethoprim (2), methotrexate (1), phenytoin (1) 6 (3.3)
Swelling of tongue (angioedema) (2) and severe dry cough
(1)
3 (2.5) Enalapril (3) 3 (1.7)
Delirium 2 (1.7) Efavirenz (2) 2 (1.1)
Thrombocytopenia 2 (1.7) Isoniazid (1), heparin (2) 3 (1.7)
Falls 1 (0.8) Diazepam (1), thioridazine (1) 2 (1.1)
Osteomalacia 1 (0.8) Phenobarbital (1), phenytoin (1) 2 (1.1)
Hypotension (orthostatic) 1 (0.8) Atenolol (1) 1 (0.6)
Syncope 1 (0.8) Metoprolol (1) 1 (0.6)
Dizziness 1 (0.8) Quinine (1) 1 (0.6)
Blurred vision 1 (0.8) Amlodipine (1) 1 (0.6)
Vertigo 1 (0.8) Metoprolol (1) 1 (0.6)
Vaginal bleeding 1 (0.8) Medroxyprogesterone acetate (1) 1 (0.6)
^suspected to have caused lactic acidosis,
* suspected to have caused Steven Johnson Syndrome,
#high dose (325mg) acetyl salicylic acid
https://doi.org/10.1371/journal.pone.0186631.t002
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a rising proportion of colliding epidemics of infectious and non-communicable diseases
demanding multiple medications with potential of interactions [11, 63], a greater prevalence
of HIV/AIDS and TB co-infection [64] with overlapping adverse effects of their medications
[6], and a less health-literate population [14]. Additionally, malnutrition and anaemia are
more common than in developed countries [65, 66]. Our study, the first in Ethiopia, identified
risk factors associated with ADRs, and characterised the reaction types and drugs implicated
in admission to the JUSH in Southwest Ethiopia.
We found that 10.3% of admissions were related to ADRs, a prevalence comparable to
other studies from South Africa [39] and Argentina [67]. Similarly, a review of studies with a
similar design to ours found comparable rates of ADRs in both developed and developing
countries [1]. More than half of the ADR-related admissions were due to hepatotoxicity
(mainly due to isoniazid and pyrazinamide) and acute kidney injury (mainly due to tenofovir,
enalapril and furosemide). Very few studies, only Patel et al. [68] from India and Mouton et al.
[39] from South Africa, have reported comparable proportions of anti-TB-induced hepatotox-
icity and tenofovir-induced renal impairment. The higher incidence of hepatotoxicity in the
current study could be due to concomitant anti-TB, ART and other medications with overlap-
ping hepatotoxic effects. In addition, there was a substantial number of patients with malnutri-
tion in the current study, and potentially the slow acetylation status of some Ethiopian patients
with isoniazid [69] could have exacerbated the hepatotoxic reactions. ADRs commonly
responsible for hospitalisation in previous studies included gastrointestinal bleeding [25, 31],
electrolyte and metabolic disturbances [8, 28, 36] and cardiovascular disorders [28, 30]. Similar
ADRs were reported in the current study, but at lower rates probably due to differences in pop-
ulation, diseases characteristics and drug therapy used.
Most of the predictors of ADRs, such as number of comorbidities [27, 28], number of drugs
[28, 29, 36], pre-existing renal failure [31, 70], pre-existing liver diseases [37] and history of
previous ADRs [37, 38], were in line with reported findings from both developed and develop-
ing countries. HIV/AIDS patients taking ART was identified as an independent predictor that
raised the risk of experiencing ADRs in South African studies [8, 39] in 2005 and 2013, respec-
tively. However, this variable was not included in the predictive model in the current study.
This is possibly due to the intrinsic relationships between HIV/AIDS and malnutrition,
Table 3. Comparison of drugs used between non-ADR and ADR patient groups.
ATC class name Non-ADR group n (%) ADR group n (%) p-value
Alimentary tract and metabolism 348 (10.1) 57 (10.1) 0.962
Blood and blood forming organs 374 (10.8) 46 (8.1) 0.085
Cardiovascular system 862 (24.9) 106 (18.9) 0.013
Dermatologicals 4 (0.1) 2 (0.4) 0.173
Genito-urinary system and sex hormones 19 (0.5) 2 (0.4) 0.556
Systemic hormonal preparations 96 (2.8) 9 (1.6) 0.113
Anti-infective for systemic use 1398 (40.5) 293 (52.1) 0.001
Antineoplastic and immunomodulating agents 0 (0.0) 1 (0.2) NAa
Musculo-skeletal system 78 (2.3) 9 (1.6) 0.331
Nervous system 188 (5.4) 24 (4.3) 0.273
Antiparasitic products 37 (1.1) 6 (1.1) 0.995
Respiratory system 52 (1.5) 7 (1.2) 0.640
Total 3456 (100.0) 562 (100.0)
aNA = Not applicable, ATC = Anatomical Therapeutic Chemical Classification
https://doi.org/10.1371/journal.pone.0186631.t003
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multiple comorbidities and polypharmacy, although multicollinearity was not detected. In
addition, the strength of the effect of HIV/AIDS patients taking ART as an independent vari-
able is likely less than that of the other variables possibly because HIV/AIDS patients taking
ART would have shown crossover-interaction with ADR-related hospitalisation. Additionally,
Table 4. Characteristics of patients experiencing ADR-related admissions and non-ADR-related admissions at Jimma Universality Specialised
Hospital.
Risk factors Non-ADR related admissions ADR-related admission p-value
Total patients N = 898 N = 103
Age, median (IQR) 40 (28–55) 40 (28–60) 0.490
Gender, female n (%) 404 (45.0) 51 (49.5) 0.382
Body mass index (kg/m2), mean ± SD 20.1±2.9 19.1±2.8 0.004
BMI (kg/m2), n (%)
<18.5kg/m2 260 (29.0) 44 (42.7)
>/ = 18.5 kg/m2 638 (71.0) 59 (57.3) 0.004
Education, n (%)
Educated 613 (68.3) 68(66.0)
Uneducated 285 (31.7) 35(34.0) 0.644
Residence, n (%)
Urban resident 421 (46.9) 64 (62.1)
Rural resident 477 (53.1) 39 (37.9) 0.003
Alcohol users, n (%) 218 (24.3) 17 (16.5) 0.080
Khat chewers, n (%) 121 (13.5) 5 (5.9) 0.141
Herbal users, n (%) 73 (8.1) 6 (5.8) 0.710
Previous ADR history, n (%) 12 (1.3) 29 (28.2) <0.001
eGFR, n (%)
<60 mL/minute/1.73m2 307 (34.2) 27 (26.2)
60 mL/minute/1.73m2 376 (41.9) 61 (59.2)
Unknown 215 (23.9) 15 (14.6) 0.003
Pre-existing renal diseases, n (%) 48 (5.3) 13 (12.6) 0.003
Pre-existing liver diseases, n (%) 70 (7.8) 20 (19.4) <0.001
Pre-existing heart failure, n (%) 232 (25.8) 27 (26.2) 0.934
HIV/AIDS patients taking ART, n (%) 79 (8.8) 29 (28.2) <0.001
TB patients taking anti-TB drugs, n (%) 171 (19.0) 36 (35.0) <0.001
Malignancy of any type, n (%) 40 (4.5) 5 (4.9) 0.853
Cerebrovascular diseases, n (%) 84 (9.4) 4 (3.9) 0.063
Diabetes with complications, n (%) 69 (7.7) 9 (8.7) 0.705
Chronic obstructive pulmonary diseases, n (%) 54 (6.0) 3 (2.9) 0.198
Peptic Ulcer Diseases, n (%) 20 (2.2) 3 (2.9) 0.660
Pre-existing hypertension, n (%) 109 (12.1) 11 (10.7) 0.666
Number of comorbidities, mean ± SD 3.2±1.2 4.1±1.4 <0.001
Number of comorbidities, n (%)
1–3 comorbidities 563 (62.7) 36 (35.0)
 4 comorbidities 335 (37.3) 67 (65.0) <0.001
Number of total medications, mean ± SD 3.9±2.1 5.6±2.7 <0.001
Number of medications, n (%)
1–5 medications 721 (80.3) 59 (57.3)
 6 medications 177 (19.7) 44 (42.7) <0.001
Admission in the preceding 3 months (1 admission(s)), n (%) 114 (12.7) 21 (20.4) 0.030
https://doi.org/10.1371/journal.pone.0186631.t004
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compared to earlier South African studies, the burden of HIV/AIDS is now markedly reduced
due to improvements in health care and greater availability of more tolerable ART. The two
South African studies were conducted in communities with a high prevalence of HIV/AIDS,
when more toxic antiretroviral drugs were in use. Finally, pharmacogenomic variations and
other clinical characteristics of patients may have contributed to this difference [69].
Patients with pre-existing renal diseases were more likely to be hospitalised with ADRs
than patients with normal renal function, as has been identified in other studies [71, 72].
About one-third of the patients presented to JUSH with an eGFR <60 mL/min/1.73m2
(Table 4), of whom, 18.5% had pre-existing renal diseases. Nearly one-third of patients were
underweight (Table 4) and patients with lower BMI were at increased risk of developing
ADRs in the current study (Table 5), which is in line with another study [73]. The combined
effect of reduced muscle mass (malnutrition) with chronic illnesses may have contributed to
a depressed eGFR despite normal serum creatinine levels, and concealed renal insufficiency
may impact on the clearance of hydrophilic drugs [74]. In addition, patients in the current
study might unintentionally be overdosed based on their weight and/or renal function
(using eGFR) that may have led them to develop ADRs. It is therefore important to evaluate
renal function to assess the potential therapeutic benefit against the risk of ADRs before initi-
ating renally cleared drugs.
Similar to previous studies [33, 75], patients with pre-existing liver diseases were more
likely to develop ADRs. Patients with liver diseases may have multiple comorbidities that
require complex medical regimens [76]. Pharmacokinetic and pharmacodynamic changes
such as a decreased drug elimination or increased toxic metabolites, alteration in drug distri-
bution or protein binding provide opportunity for adverse reactions [33]. In addition, some
drugs (such as anti-TB and ART) commonly used in the sample population are more likely to
be associated with hepatotoxicity, in contrast to drugs used in developed countries.
We found that ADR patients were prescribed a higher number of medications compared to
non-ADR patients. That means, increasing medical complexity, both number of co-morbidi-
ties and number of medications, were associated with an increased risk for ADR-related hospi-
talisations. This is clearly described in the literature [28, 30, 37].
Patients with a previous ADR history were more likely to be admitted with ADRs which is
consistent with other studies [37, 38]. This might be explained by immunological reactions
tending to become worse on repeated exposure due to immunologic memory or cross-reaction
Table 5. Regression model of ADR-related hospitalisation.
Predictors Crude Adjusted
OR (95%CI) p-value OR (95%CI) p-value
BMI < 18.5kg/m2 1.83 (1.21–2.78) 0.004 1.69 (1.10–2.62) 0.047
Pre-existing renal diseases 2.56 (1.34–4.90) 0.005 2.84 (1.38–5.85) 0.004
Pre-existing liver diseases 2.85 (1.65–4.92) <0.001 2.61 (1.38–4.96) 0.003
Number of comorbidities 4 3.13 (2.04–4.79) <0.001 2.09 (1.27–3.44) 0.004
Number of medications 6 3.04 (1.99–4.64) <0.001 2.02 (1.26–3.25) 0.004
History of previous ADR 28.94 (14.18–59.05) <0.001 24.27 (11.29–52.17) <0.001
Alcohol users 1.62 (0.94–2.79) 0.080 2.45 (1.29–4.65) 0.060
Urban residence 1.86 (1.22–2.83) 0.004 1.50 (0.89–2.52) 0.123
Khat chewers 1.46 (0.88–2.41) 0.141 1.03 (0.58–1.82) 0.932
TB patients taking anti-TB dugs 2.28 (1.47–3.54) <0.001 1.41 (0.79–2.50) 0.241
HIV/AIDS patients taking ART 4.06 (2.49–6.62) <0.001 1.33 (0.67–2.65) 0.416
Admission in the preceding 3 months 1.76 (1.05–2.96) 0.030 0.99 (0.51–1.91) 0.965
https://doi.org/10.1371/journal.pone.0186631.t005
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to alternative drugs, or because no alternative drugs are available more toxic alternatives must
be used. Most of the ADRs observed were preventable. Most of the ADRs in the current study
occurred due to lack of close review of patients’ previous clinical and medication-related prog-
ress. ADR prevention could have been improved with better knowledge of patients’ medical
and medication history and associated risk factors.
The ADR-related hospitalisation risk prediction model demonstrated a capacity of 79.0% to
discriminate patients who are at risk of ADR-related hospitalisation and those patients who
are not. The sensitivity and specificity of the ADR-risk prediction model was 59.2% and 86.6%,
respectively, which suggests that it can moderately rule-in patients at risk of ADRs and
strongly rule-out those patients not at risk of ADRs. To our knowledge, there is no previously
developed similar ADR-risk prediction model in similar study populations aged18 years,
especially in low and middle-income countries. Previous models developed by Zopf et al. [37]
and Parameswaran et al. [57] showed comparable results (predictive abilities of 80.0% and
70.0%, respectively), but these models were developed in different populations with different
clinical characteristics and drug therapy. Our model was further augmented by an ADR pre-
ventability assessment using Schumock and Thornton’s preventability assessment criteria, in
which the majority of the ADRs were preventable provided these risk factors were reviewed
and monitored closely. Although our ADR risk prediction model was not validated in other
populations, the majority of the variables identified as independent predictors of ADRs have
been described in previous studies [37, 57], suggesting that it is a useful model to assist health-
care practitioners to moderately identify patients at risk for ADRs for implementation of inter-
vention strategies.
Limitations and strengths
Due to the cross-sectional nature of this study, we were only able to consider the incidence
of ADRs at a time, so there is a need for future longitudinal studies to consider the incidence
of initial and repeat events, and interventional strategies to identify root causes and reduce
ADR-related burdens. The self-reported responses for previous ADR history, for instance,
may be limited by recall bias and could have influenced the identified predictors of ADRs,
especially in patients taking multiple medications for chronic illnesses. Some questions in
the Naranjo causality assessment tool were designed for controlled clinical trials; they were
not feasible nor ethical for clinical practice, such as observing effects on giving placebo.
Commonly used over-the-counter medicines, contraceptives, topical agents, and herbal rem-
edies were not typically recorded in drug histories, which may have resulted in underestima-
tion of the rate of ADR-related admissions. The results of this study should be extrapolated
to other countries with caution, as the study findings depend on the patient characteristics,
disease distribution, healthcare infrastructure, detection methods and definitions of ADRs
adopted.
The strength of our study is the prospective identification of ADRs immediately upon
admission, allowing for accurate evaluation of the clinical presentation and laboratory parame-
ters. We used a three-step process in ADR assessment, evaluating individual patient’s clinical
and laboratory parameters, causality assessment using the Naranjo algorithm followed by con-
sensus review with a senior supervising internist, to help mitigate the subjectivity associated
with interpretation of some ADRs. Our study is the first to identify independent predictors of
ADR-related hospitalisation in Ethiopian patients. Our yearlong sampling avoided the bias
associated with anti-infective use pattern due to seasonal variation. Our study was conducted
in a teaching and referral hospital serving a population of 15 million; therefore, our results
allow extrapolation to other settings in the southwest of Ethiopia.
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Conclusions
ADRs were a common cause of hospitalisation in adults admitted to medical wards of the
JUSH. The majority of ADRs were preventable, highlighting the need for close monitoring
and review of patients with lower BMI, previous ADR history, pre-existing renal and liver dis-
eases, multiple comorbidities and medications. The ADR-related hospitalisation risk predic-
tion model demonstrated some ability to identify patients at higher risk for ADRs, and clearly
identify patients at lower risk of ADRs. ADR predictors should be integrated into clinical path-
ways and pharmacovigilance systems. However, validation and refinement of the model is nec-
essary prior to its implementation in routine clinical practice. The prevention of incident ADR
may be of paramount importance, as previous ADR was a strong predictor of subsequent
events in this patient population. Assessment of ADR causality and effective use of a pharma-
covigilance system to monitor drug response in patients should be considered at ambulatory
care units of all health care levels to minimise the burden of admissions related to ADRs by tar-
geting the occurrence of preventable reactions.
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